Kinnate Biopharma Inc. Stock Price, News & Analysis

Kinnate Biopharma Inc. (Nasdaq: KNTE) has announced a collaboration with Guardant Health to explore BRAF alterations in over 175,000 patients. The study targets advanced solid tumors, highlighting the prevalence of Class II and III alterations, which affect more than half of BRAF-positive patients. Preliminary analyses show that approximately 55% of identified patients have Class II and III alterations, especially in common cancers like NSCLC, Melanoma, and CRC. This partnership aims to inform the development of targeted therapies for these difficult-to-treat cancers.

Kinnate Biopharma (Nasdaq: KNTE) announced that Chief Scientific Officer Dr. Eric Murphy will step down on December 3, 2021, to pursue another opportunity but will join the Scientific Advisory Board. The company has recently achieved significant milestones, including obtaining an IND for KIN-2787 and initiating a Phase 1 clinical trial for BRAF mutant advanced solid tumors. Kinnate aims to leverage its discovery engine to develop small molecule kinase inhibitors targeting genomically defined cancers, with further pipeline development expected in 2022.

Kinnate Biopharma (Nasdaq: KNTE) announces the expansion of its first-in-human, multicenter Phase 1 trial of KIN-2787, targeting BRAF mutant advanced solid tumors, now actively recruiting at three sites.

KIN-2787 is designed to be a pan-RAF inhibitor addressing Class I, II, and III BRAF mutations, potentially offering first-line treatment options. The trial is anticipated to enroll around 115 patients, focusing on dose escalation and evaluating efficacy in diverse cancer types. The progress of this study is crucial in addressing unmet needs in cancer treatment.

Kinnate Biopharma (Nasdaq: KNTE) has announced details of its first in human trial (KN-8701) for KIN-2787, a pan-RAF inhibitor targeting multiple BRAF mutations in solid tumors. The trial is actively recruiting patients and will be presented at the AACR-NCI-EORTC Conference from October 7-10, 2021. KIN-2787 aims to offer a first-line targeted therapy option for patients with lung cancer, melanoma, and other tumors. The first patient has commenced treatment at the Sarah Cannon Research Institute, highlighting ongoing collaborations in this critical clinical study.

Kinnate Biopharma has announced promising preclinical results for its lead FGFR inhibitor, KIN-3248, which targets mutations in FGFR2 and FGFR3, common in various cancers. The findings, presented at the JCA-AACR Precision Cancer Medicine Conference, indicate that KIN-3248 shows broad-spectrum efficacy against both primary mutations and those causing resistance to existing therapies. The company plans to submit an IND application to the FDA in early 2022, signaling progress in its development pipeline.

Kinnate Biopharma Inc. (Nasdaq: KNTE) announced the dosing of its first patient in the Phase 1 trial for KIN-2787, targeting BRAF mutation-positive solid tumors. The trial aims to evaluate the safety and efficacy of KIN-2787, a pan-RAF inhibitor, among 115 patients. Financially, Kinnate reported a net loss of $21.4 million for Q2 2021, up from $7.6 million in Q2 2020, with R&D expenses increasing to $16.2 million. The company ended the quarter with cash and equivalents of $365.1 million. Key management appointments were made to strengthen leadership in clinical development and corporate strategy.

Kinnate Biopharma Inc. (Nasdaq: KNTE) announced its CEO, Nima Farzan, will participate in the virtual 2021 Wedbush PacGrow Healthcare Conference on August 10-11, 2021. Farzan will join the panel titled “Bullseye - Targeted Oncology Part 1” on August 10 at 10:55 AM ET. Kinnate's management will hold investor meetings during the event. A live webcast of the panel will be available on Kinnate's website, with a replay accessible for 30 days post-event. Kinnate focuses on developing small molecule kinase inhibitors for difficult-to-treat cancers.

Kinnate Biopharma Inc. (Nasdaq: KNTE) will participate in the William Blair Biotech Focus Conference 2021 on July 15, 2021. CEO Nima Farzan will speak on the panel titled “Next Generation Small Molecules in Oncology” at 9:00 AM ET. The event is virtual, and members of Kinnate's management will also hold investor meetings during the conference. Interested parties can watch a live webcast on Kinnate's website, with a replay available for 30 days post-event. Kinnate focuses on developing small molecule kinase inhibitors for challenging, genomically defined cancers.

Kinnate Biopharma (Nasdaq: KNTE) has appointed Dr. Helen Sabzevari to its Board of Directors. A recognized leader in oncology, Dr. Sabzevari brings valuable experience from her roles at Precigen and Merck Serono. Her expertise in bridging cancer cell biology and immunology is expected to enhance Kinnate's development of their lead program, KIN-2787. CEO Nima Farzan highlighted her track record and patient-first approach, indicating her potential impact on the company's growth strategies as Kinnate prepares to initiate clinical studies.